Ondine Biomedical Inc. (OBIMF) Discusses Positive LANTERN Phase III Results and Advances in Surgical Site Infection Prevention Transcript
Operator
Good afternoon, and welcome to the Ondine Biomedical Investor presentation. [Operator Instructions] Before we begin, I’d like to submit the following poll. I’d now like to hand you over to the management team. Nicolas, good afternoon, sir.
Nicolas Loebel
President, CTO & Executive Director
Good afternoon. Thank you so much to everyone at Investor Meet and to 5654 and the help we received from Events in our company. Thank you to all participants in this webcast. I’ll be talking today about our LANTERN Phase III positive top-line results and questions thereto. I’m going to start by making it clear that this is an investigational product in the U.S. and therefore, it’s not approved in the U.S. It is not commercially available for sale in the U.S.
It is limited by federal law to investigational use only. Outside of the United States, we’re a commercial for-profit company, and we sell this product. So I will be referring very carefully within the United States to the results of the LANTERN study as being an investigational product. Just a quick primer again on who we are and what the case is for what we’re doing. We’ve developed a brand-new approach to disinfection.
It’s fast. It doesn’t produce resistance. It’s designed to remove microbes without using antibiotics, which then, of course, removes the burden of antibiotic resistance development. It is in clinical use today in multiple countries. And in the United States, we have received QIDP designation and Fast Track status for surgical site infection prevention. Just a reminder that there are over 300 million surgical procedures performed globally each year, 35 million major surgeries in the United
